

ENDO PHARMACEUTICALS HOLDINGS INC

Form 4

December 02, 2005

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
KELSO PARTNERS V L P

2. Issuer Name **and** Ticker or Trading
Symbol
**ENDO PHARMACEUTICALS
HOLDINGS INC [ENDP]**

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
320 PARK AVENUE
(Street)

3. Date of Earliest Transaction
(Month/Day/Year)
11/29/2005

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

NEW YORK, NY 10022

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$.01 per share	11/29/2005		X		3,879	D	\$ 2.42	15,872,376	I	By Endo Pharma LLC
Common Stock, par value \$.01 per share	11/29/2005		X		6,145	D	\$ 2.42	15,866,231	I	By Endo Pharma LLC
Common Stock, par value \$.01 per share	11/29/2005		X		10,880	D	\$ 2.42	15,855,351	I	By Endo Pharma LLC

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

Common Stock, par value \$.01 per share	11/29/2005	X	4,760	D	\$ 2.42	15,850,591	I	By Endo Pharma LLC
Common Stock, par value \$.01 per share	11/29/2005	X	8,706	D	\$ 2.42	15,841,885	I	By Endo Pharma LLC
Common Stock, par value \$.01 per share ⁽¹⁾	11/29/2005	X	17,083	D	\$ 2.42	15,824,802	I	By Endo Pharma LLC ⁽²⁾ ⁽³⁾
Common Stock, par value \$.01 per share ⁽¹⁾	11/29/2005	X	6,509	D	\$ 3	15,818,292	I	By Endo Pharma LLC ⁽²⁾ ⁽³⁾
Common Stock, par value \$.01 per share ⁽¹⁾	11/29/2005	X	738	D	\$ 3	15,817,554	I	By Endo Pharma LLC ⁽²⁾ ⁽³⁾
Common Stock, par value \$.01 per share ⁽¹⁾	11/29/2005	X	4,536	D	\$ 3	15,813,018	I	By Endo Pharma LLC ⁽²⁾ ⁽³⁾
Common Stock, par value \$.01 per share ⁽¹⁾	11/29/2005	X	4,911	D	\$ 3.42	15,808,108	I	By Endo Pharma LLC ⁽²⁾ ⁽³⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number

									of Shares
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	3,879	10/13/2005	08/26/2007	Common Stock	3,879	
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	6,145	10/13/2005	08/26/2007	Common Stock	6,145	
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	10,880	10/13/2005	08/26/2007	Common Stock	10,880	
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	4,760	10/13/2005	08/26/2007	Common Stock	4,760	
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	8,706	10/13/2005	08/26/2007	Common Stock	8,706	
Call Option (obligation to sell)	\$ 2.42	11/29/2005	X	17,083	10/13/2005	08/26/2007	Common Stock	17,083	
Call Option (obligation to sell)	\$ 3	11/29/2005	X	6,509	10/13/2005	08/26/2007	Common Stock	6,509	
Call Option (obligation to sell)	\$ 3	11/29/2005	X	738	10/13/2005	08/26/2007	Common Stock	738	
Call Option (obligation to sell)	\$ 3	11/29/2005	X	4,536	10/13/2005	08/26/2007	Common Stock	4,536	
Call Option (obligation to sell)	\$ 3.42	11/29/2005	X	4,911	10/13/2005	08/26/2007	Common Stock	4,911	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KELSO PARTNERS V L P 320 PARK AVENUE NEW YORK, NY 10022		X		

Signatures

James J.
Connors II

12/02/2005

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Kelso Partners V, L.P. (KP V") is the designated filer.

KP V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KP V shares investment and voting power along with the other members of Endo Pharma LLC with respect to securities owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.

Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KP V, by virtue of his status as a general partner of the general partner of KP V, and each individual shares investment and voting power along with the other general partners of KP V, but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.